Bethesda, Maryland178Chicago, Illinois76Pittsburgh, Pennsylvania70St Louis, Missouri66Oklahoma City, Oklahoma65Columbus, Ohio64New York, New York58Boston, Massachusetts52Atlanta, Georgia51Richmond, Virginia50Los Angeles, California49Ann Arbor, Michigan46Baltimore, Maryland46Philadelphia, Pennsylvania46Sacramento, California45

Trials now recruiting

The 250 trials with the most US sites, of 274 currently recruiting.

Trial	Phase	US sites
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · Anchorage, Alaska	Phase 3	1,150
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyNCT04269902 · Birmingham, Alabama	Phase 3	623
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · Anchorage, Alaska	Phase 3	604
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · Birmingham, Alabama	Phase 2	581
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · Birmingham, Alabama	Phase 3	543
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyNCT05987241 · Phoenix, Arizona	Phase 2/3	491
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · Birmingham, Alabama	Phase 2	479
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationNCT04858334 · Anchorage, Alaska	Phase 2	451
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialNCT04402788 · Birmingham, Alabama	Phase 2/3	416
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaNCT05256225 · Birmingham, Alabama	Phase 3	404
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabNCT05675410 · Birmingham, Alabama	Phase 3	392
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialNCT06203600 · Little Rock, Arkansas	Phase 2/3	374
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · Anchorage, Alaska	Phase 2	345
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)NCT05564390 · Birmingham, Alabama	Phase 2	336
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · Fayetteville, Arkansas	Phase 3	322
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNCT07061977 · Birmingham, Alabama	Phase 3	303
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaNCT03739814 · Birmingham, Alabama	Phase 2	276
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · Jonesboro, Arkansas	Phase 3	273
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaNCT06337318 · Birmingham, Alabama	Phase 3	270
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerNCT04628767 · Kingman, Arizona	Phase 2/3	258
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNCT06422806 · Phoenix, Arizona	Phase 3	246
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerNCT07198074 · Birmingham, Alabama	Phase 3	243
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyNCT05136196 · Phoenix, Arizona	Phase 2	225
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)NCT06317649 · Birmingham, Alabama	Phase 2	225
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)NCT05554406 · Birmingham, Alabama	Phase 2	215
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)NCT04546399 · Birmingham, Alabama	Phase 2	209
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNCT06589804 · Little Rock, Arkansas	Phase 3	192
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)NCT06126276 · Birmingham, Alabama	Phase 2	188
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaNCT05691478 · Birmingham, Alabama	Phase 2/3	181
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaNCT04671667 · Birmingham, Alabama	Phase 2	178
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)NCT05554393 · Birmingham, Alabama	Phase 2	169
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialNCT07061964 · Birmingham, Alabama	Phase 2	160
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerNCT06524544 · Phoenix, Arizona	Phase 3	159
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaNCT06172296 · Birmingham, Alabama	Phase 3	156
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)NCT06124157 · Birmingham, Alabama	Phase 2	141
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaNCT04840602 · Tucson, Arizona	Phase 2	138
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNCT05112601 · Birmingham, Alabama	Phase 2	138
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNCT06770582 · Fayetteville, Arkansas	Phase 2	132
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)NCT06672146 · Tucson, Arizona	Phase 2	129
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaNCT06317662 · Birmingham, Alabama	Phase 2	112
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)NCT05099003 · Birmingham, Alabama	Phase 1/2	109
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerNCT07195734 · Tucson, Arizona	Phase 2	102
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNCT06649812 · Tucson, Arizona	Phase 2	86
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerNCT06029270 · Dublin, California	Phase 2	83
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerNCT06900595 · La Jolla, California	Phase 2	77
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)NCT06064097 · Birmingham, Alabama	Phase 2	76
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · Jonesboro, Arkansas	Phase 3	72
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgeryNCT06050252 · Irvine, California	Phase 2	58
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONCT03816345 · Birmingham, Alabama	Phase 1	51
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerNCT04172532 · Duarte, California	Phase 1/2	44
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775 · Duarte, California	Phase 1/2	43
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaNCT06860594 · Duarte, California	Phase 1	43
The Vanguard Study: Testing a New Way to Screen for CancerNCT06995898 · Pleasanton, California	Not applicable	39
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemNCT07042295 · Birmingham, Alabama	Phase 2	38
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialNCT05327010 · Duarte, California	Phase 2	36
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentNCT05432804 · Phoenix, Arizona	Phase 1/2	36
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerNCT05198830 · Buena Park, California	Phase 2	34
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialNCT05773274 · Birmingham, Alabama	Phase 2	33
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialNCT07388524 · Newark, Delaware	Phase 3	33
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 · Orange, California	Phase 2	30
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorNCT04616560 · Birmingham, Alabama	Phase 1/2	29
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNCT04665739 · Birmingham, Alabama	Phase 2	29
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerNCT04633239 · Phoenix, Arizona	Phase 1	27
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentNCT05859334 · Aurora, Colorado	Phase 2	27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)NCT06311214 · Duarte, California	Phase 2	27
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerNCT05896839 · La Jolla, California	Phase 1/2	26
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessNCT05691491 · Irvine, California	Phase 1/2	23
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair GenesNCT05687110 · Duarte, California	Phase 1	22
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable CancersNCT05803382 · Irvine, California	Phase 1	22
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseNCT05886049 · Orange, California	Phase 1	22
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesNCT06484062 · New Haven, Connecticut	Phase 1	22
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNCT06311227 · Duarte, California	Phase 2	21
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)NCT04301076 · Atlanta, Georgia	Phase 1	19
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneNCT05372614 · Duarte, California	Phase 1	18
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)NCT07281430 · Birmingham, Alabama	Not applicable	18
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerNCT05172245 · Tampa, Florida	Phase 1	17
Collection of Tissue Samples for Cancer ResearchNCT00900198 · Sacramento, California	—	16
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaNCT05711615 · Los Angeles, California	Phase 1	16
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerNCT05950464 · Augusta, Georgia	Phase 1	14
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaNCT06465316 · Phoenix, Arizona	Phase 1	14
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerNCT04981509 · La Jolla, California	Phase 2	13
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialNCT05333458 · Los Angeles, California	Phase 2	13
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsNCT05691465 · Duarte, California	Phase 2	13
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerNCT06696768 · Gainesville, Florida	Phase 1	13
Precision-Based Genomics in Prostate CancerNCT04706663 · La Jolla, California	—	11
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialNCT06184750 · Tucson, Arizona	Phase 2	11
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyNCT06439836 · Duarte, California	Phase 1	11
Connect for Cancer Prevention Study (Connect)NCT04609072 · Denver, Colorado	—	10
Biospecimen Procurement for Head and Neck DisordersNCT03429036 · Washington D.C., District of Columbia	—	9
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaNCT05272384 · Birmingham, Alabama	Phase 1	9
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNCT05687123 · Duarte, California	Phase 1	9
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyNCT07003295 · Duarte, California	Phase 2	9
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNCT07012031 · Sacramento, California	Phase 1/2	9
Obeticholic Acid for Prevention in Barrett's EsophagusNCT04939051 · Kansas City, Kansas	Phase 2	8
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...NCT05621291 · Los Angeles, California	Not applicable	8
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT06015880 · Duarte, California	Phase 1	8
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerNCT06654037 · Irvine, California	Phase 1	8
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaNCT07012044 · Birmingham, Alabama	Phase 1	8
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaNCT07061951 · Duarte, California	Phase 2	8
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNCT07069699 · Irvine, California	Phase 1/2	8
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerNCT04585958 · Phoenix, Arizona	Phase 1	7
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · Los Angeles, California	Phase 1	7
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)NCT02544022 · Washington D.C., District of Columbia	—	6
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerNCT05422794 · Boston, Massachusetts	Phase 1	6
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsNCT05687136 · Bethesda, Maryland	Phase 1	6
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's EsophagusNCT06732388 · Kansas City, Kansas	Phase 2	6
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNCT06980038 · Irvine, California	Phase 2	6
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal CancerNCT07147231 · Washington D.C., District of Columbia	Phase 1/2	6
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesNCT01109394 · Washington D.C., District of Columbia	—	5
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNCT05019716 · Los Angeles, California	Phase 1/2	5
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201NCT05630794 · Ann Arbor, Michigan	Phase 1	5
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO TrialNCT06022822 · Los Angeles, California	Phase 2	5
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaNCT07281417 · Irvine, California	Phase 2	5
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsNCT03816319 · Tampa, Florida	Phase 1	4
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerNCT05111561 · Boston, Massachusetts	Phase 1	4
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerNCT05941520 · Duarte, California	Phase 2	4
Testing RG1-VLP Vaccine to Prevent HPV-related CancersNCT05985681 · Birmingham, Alabama	Phase 1	4
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialNCT06811116 · Irvine, California	Phase 1/2	4
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNCT06965114 · Bethesda, Maryland	Phase 1/2	4
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid TumorsNCT03739827 · Bethesda, Maryland	—	3
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsNCT05053971 · New Haven, Connecticut	Phase 1/2	3
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy SmokersNCT05121051 · Tucson, Arizona	Phase 2	3
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNCT05237986 · Los Angeles, California	—	3
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionNCT06195306 · Kansas City, Kansas	Phase 2	3
Cancer in Inherited Bone Marrow Failure SyndromesNCT00027274 · Bethesda, Maryland	—	2
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaNCT00040352 · Bethesda, Maryland	—	2
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyNCT01247597 · Bethesda, Maryland	—	2
Clinical and Genetic Studies of Li-Fraumeni SyndromeNCT01443468 · Bethesda, Maryland	—	2
Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNCT04222413 · Fairway, Kansas	Phase 1	2
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathiesNCT04888936 · Bethesda, Maryland	—	2
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesNCT04959175 · Bethesda, Maryland	Phase 1/2	2
Rare Tumors and Cancer Predisposition in Individuals and FamiliesNCT05350761 · Bethesda, Maryland	—	2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationNCT05436418 · Duarte, California	Phase 1/2	2
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)NCT06507748 · Washington D.C., District of Columbia	Not applicable	2
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · Boston, Massachusetts	Phase 1	2
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaNCT07156227 · Pittsburgh, Pennsylvania	Phase 1	2
Psychological Benefits of a Normalized Camping Experience for Children With CancerNCT00001186 · Bethesda, Maryland	—	1
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersNCT00001238 · Bethesda, Maryland	—	1
Evaluation for NCI Surgery Branch Clinical Research ProtocolsNCT00001823 · Bethesda, Maryland	—	1
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerNCT00006518 · Bethesda, Maryland	—	1
Evaluation of Late Effects and Natural History of Disease in Patients Treated With RadiotherapyNCT00026650 · Bethesda, Maryland	—	1
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseNCT00026884 · Bethesda, Maryland	—	1
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney CancerNCT00033137 · Bethesda, Maryland	—	1
Collection of Blood From Patients With CancerNCT00034216 · Bethesda, Maryland	—	1
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal CancerNCT00050752 · Bethesda, Maryland	—	1
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma MultiformeNCT00083512 · Bethesda, Maryland	—	1
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host DiseaseNCT00092235 · Bethesda, Maryland	—	1
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningNCT00242723 · Bethesda, Maryland	—	1
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesNCT00451022 · Bethesda, Maryland	—	1
Collection of Blood From Patients With Prostate CancerNCT00923221 · Bethesda, Maryland	—	1
Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsNCT01005654 · Bethesda, Maryland	—	1
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentNCT01087333 · Bethesda, Maryland	—	1
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerNCT01174121 · Bethesda, Maryland	Phase 2	1
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal CancerNCT01313442 · Bethesda, Maryland	—	1
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisNCT01441089 · Bethesda, Maryland	—	1
Natural History Study of Children and Adults With Medullary Thyroid CancerNCT01660984 · Bethesda, Maryland	—	1
Tissue Collection for Studies of Lymph CancerNCT01676805 · Bethesda, Maryland	—	1
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation TherapyNCT01834001 · Bethesda, Maryland	—	1
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerNCT01915225 · Bethesda, Maryland	—	1
Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaNCT01950572 · Bethesda, Maryland	—	1
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerNCT02133196 · Bethesda, Maryland	Phase 2	1
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsNCT02146170 · Bethesda, Maryland	—	1
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer TissueNCT02379429 · Bethesda, Maryland	—	1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...NCT02390752 · Bethesda, Maryland	Phase 1	1
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer TissueNCT02594202 · Bethesda, Maryland	—	1
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast CancerNCT02610413 · Boston, Massachusetts	—	1
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast CancerNCT02610426 · Boston, Massachusetts	—	1
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast CancerNCT02610439 · Boston, Massachusetts	—	1
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabNCT02621021 · Bethesda, Maryland	Phase 2	1
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsNCT02682667 · Bethesda, Maryland	—	1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNCT02830724 · Bethesda, Maryland	Phase 1/2	1
Clonal Evolution in Follicular LymphomaNCT03190928 · Bethesda, Maryland	—	1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsNCT03190941 · Bethesda, Maryland	Phase 1/2	1
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaNCT03206060 · Bethesda, Maryland	Phase 2	1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNCT03223610 · Bethesda, Maryland	Phase 1/2	1
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasNCT03258567 · Bethesda, Maryland	Phase 2	1
Sample Collection and Tracking for the Developmental Therapeutics ClinicNCT03269578 · Bethesda, Maryland	—	1
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseNCT03300830 · Bethesda, Maryland	—	1
Profiling of Radiological Factors in Treatment and Outcomes in Prostate CancerNCT03354416 · Bethesda, Maryland	—	1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid TumorsNCT03366116 · Bethesda, Maryland	Phase 1	1
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerNCT03412877 · Bethesda, Maryland	Phase 2	1
Men at High Genetic Risk for Prostate CancerNCT03805919 · Bethesda, Maryland	—	1
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1NCT03830229 · Bethesda, Maryland	—	1
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialNCT03907475 · Bethesda, Maryland	Phase 2	1
Children and Adults With ChordomaNCT03910465 · Bethesda, Maryland	—	1
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaNCT04002947 · Bethesda, Maryland	Phase 2	1
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsNCT04074135 · Bethesda, Maryland	Phase 2	1
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)NCT04086485 · Bethesda, Maryland	Phase 1/2	1
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceNCT04235764 · Bethesda, Maryland	—	1
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesNCT04235777 · Bethesda, Maryland	Phase 1	1
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaNCT04303117 · Bethesda, Maryland	Phase 1/2	1
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNCT04322383 · Bethesda, Maryland	Phase 2	1
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition SyndromeNCT04431024 · Bethesda, Maryland	—	1
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelNCT04449549 · Bethesda, Maryland	Phase 2	1
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisNCT04557969 · Bethesda, Maryland	—	1
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerNCT04633252 · Bethesda, Maryland	Phase 1/2	1
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersNCT04645160 · Bethesda, Maryland	Phase 1/2	1
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate CancerNCT04692675 · Bethesda, Maryland	Not applicable	1
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasNCT04750928 · Bethesda, Maryland	Phase 1/2	1
A Natural History Study of Children and Adults With Olfactory NeuroblastomaNCT04755205 · Bethesda, Maryland	—	1
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNCT04815356 · Bethesda, Maryland	Phase 1	1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesNCT04847063 · Bethesda, Maryland	Phase 1	1
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNCT04902443 · Bethesda, Maryland	Phase 1	1
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesNCT04923178 · Bethesda, Maryland	—	1
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaNCT04941274 · Bethesda, Maryland	Phase 1/2	1
Natural History of KSHV-Associated Multicentric Castleman s DiseaseNCT04968288 · Bethesda, Maryland	—	1
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesNCT05003895 · Bethesda, Maryland	Phase 1	1
PT-112 in Subjects With Thymoma and Thymic CarcinomaNCT05104736 · Bethesda, Maryland	Phase 2	1
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaNCT05155033 · Bethesda, Maryland	Phase 2	1
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyNCT05155046 · Bethesda, Maryland	Phase 2	1
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)NCT05237934 · Bethesda, Maryland	—	1
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaNCT05286814 · Bethesda, Maryland	Phase 2	1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesNCT05327023 · Bethesda, Maryland	Phase 1/2	1
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDSNCT05350748 · Bethesda, Maryland	—	1
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation TherapyNCT05361798 · Bethesda, Maryland	Phase 2	1
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled TrialNCT05361811 · Bethesda, Maryland	Not applicable	1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · Bethesda, Maryland	Phase 1	1
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesNCT05442515 · Bethesda, Maryland	Phase 1/2	1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...NCT05470491 · Bethesda, Maryland	Phase 1/2	1
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyLNCT05588128 · Bethesda, Maryland	—	1
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsNCT05588141 · Bethesda, Maryland	Phase 1/2	1
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesNCT05588154 · Bethesda, Maryland	—	1
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate TumorNCT05616650 · Bethesda, Maryland	Phase 2	1
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)NCT05665361 · Bethesda, Maryland	Phase 1/2	1
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid CancersNCT05691517 · Bethesda, Maryland	Phase 1	1
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerNCT05777603 · Bethesda, Maryland	Phase 1	1
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)NCT05849480 · Bethesda, Maryland	Phase 1/2	1
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNCT05907759 · Bethesda, Maryland	Phase 2	1
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)NCT06041503 · Bethesda, Maryland	Phase 2	1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsNCT06041516 · Bethesda, Maryland	Phase 1	1
A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNCT06066138 · Bethesda, Maryland	Phase 1	1
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyNCT06090669 · Bethesda, Maryland	Phase 1	1
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyNCT06096870 · Bethesda, Maryland	Phase 2	1
18F-Fluciclovine PET/CT in Multiple MyelomaNCT06103838 · Bethesda, Maryland	Phase 2	1
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)NCT06149481 · Bethesda, Maryland	Phase 1/2	1
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate CancerNCT06161506 · Bethesda, Maryland	Phase 2	1
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsNCT06161519 · Bethesda, Maryland	Phase 1/2	1
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...NCT06161532 · Bethesda, Maryland	Phase 2	1
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaNCT06161545 · Bethesda, Maryland	Phase 2	1
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNCT06176989 · Bethesda, Maryland	Phase 2	1
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)NCT06222203 · Bethesda, Maryland	—	1
Studying TAK-243 in Patients With Advanced CancerNCT06223542 · Bethesda, Maryland	Phase 1	1
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerNCT06223568 · Bethesda, Maryland	Phase 2	1
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)NCT06228066 · Bethesda, Maryland	Phase 2	1
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismNCT06246357 · Bethesda, Maryland	Phase 2	1
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerNCT06253494 · Bethesda, Maryland	Phase 1/2	1
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNCT06303193 · Bethesda, Maryland	Phase 1/2	1
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaNCT06344130 · Bethesda, Maryland	Phase 1	1
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsNCT06364410 · Houston, Texas	Phase 1	1
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasNCT06364423 · Bethesda, Maryland	Phase 1/2	1

About these figures

Lead sponsor only. These are trials where National Cancer Institute (NCI) is recorded on ClinicalTrials.gov as the lead sponsor. Trials they collaborate on, or host at their sites for another sponsor, are not counted, so their real involvement in clinical research is larger than the figure here.

Counts cover trials recruiting at US sites and are refreshed monthly. See all sponsors for how this compares with the rest of the field.

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.